PROCESS FOR PRODUCING TRANSFORMED CELL

Abstract: A process for producing transformed cells by introducing foreign genes into target cells through piercing, which comprises the step of culturing the target cells having the foreign genes injected thereinto in the presence of a cell adhesion-active substance; and a kit for producing transformed cells suitable for use in the above method and containing as the essential ingredients the cells to be transformed with foreing genes by this method and a cell adhesion-active substance.

Description: TECHNICAL FIELD The present invention relates to a method for production of transfected cells, more particularly, a method which makes possible to effectively transfer a foreign gene into target cells in the field such as cell technology, genetic engineering, developmental engineering and the like. BACKGROUND ART As a method for transferring a foreign gene into target cells, there are known a calcium phosphate method, a DEAE-dextran method, a liposome method, an electroporation method, a microinjection method, a particle gun method and the like. All of these methods have advantages and disadvantages in respect of manipulation procedures, efficacy, damage on cells and the like. Among these methods, a perforation method such as an electroporation method, a microinjection method, a particle gun method and the like can easily handle cells without using special reagents and have good transfer efficacy. However, damage of cells by perforation can not be avoided. The object of the present invention is to provide a method for improving the transfer efficacy when a foreign gene is transferred into target cells by a perforation method to produce transfected cells. SUMMARY OF THE INVENTION The first aspect of the present invention relates to a method for production of transfected cells and is characterized in that said aspect includes a step of, after injection of a foreign gene into target cells using a perforation method, culturing the cells in the presence of a cell-adhering active substance, in a method for production of a transfected cell using a perforation method. The second aspect of the present invention relates to gene-transferred cells which are produced by the method of the present invention. The third aspect of the present invention relates to a kit for production of transfected cells, which is used for a method for production of transfected cells according to the first aspect of the present invention and is characterized in that said aspect contains a cell-adhering active substance. DETAILED DESCRIPTION OF THE INVENTION The method of the present invention is characterized in that, after a foreign gene is transferred into target cells using a perforation method, the cell is cultured in the presence of a substance having the cell adhesive activity. As used herein, the perforation method means a method for injection of a gene by perforating a cell wall, including an electroporation method, a microinjection method, a particle gun method and the like. The electroporation method is described, for example, in Tanpakushitsu, Kakusan, Koso, volume 31, page 1591-1603 (1986). The microinjection method is described, for example, in Cell, volume 22, page 479-488 (1980). The particle gun method is described, for example, in Technique, volume 3, page 3-16 (1991). These methods include the known methods used for transferring a gene into cells. For cells used in these perforation methods, for example, animal cells may be prepared according to a known method ["Shin-Seikagaku Jikkenkoza 18, Saibobaiyogijyutsu", 1st edition (1990), edited by Nippon Seikagakugakkai, published by Tokyo Kagakudojin] or cultured animal cells may be used. As used herein, a cell-adhering active substance refers to a substance having the cell-adhering activity, that is, the activity to make target cells adhere to a cell, or to an extracellular matrix which is a substance filling a space between cells in the tissue, or to a material such as plastic, glass and the like. In the present invention, any substances having the activity can be used as long as they give no adverse effects on transfection of target cells. Such the activity is to fix cells, for example, to a culture wear covered with a cell-adhering active substance while maintaining the cell in its form, or in the spreaded form, that is, in the changed form after the cell has been spreaded in one or more directions. Attachment between the cell-adhering active substance and the target cell can be assayed using a conventional method. The method includes, for example, a method described in Nature, 352 : 438-441 (1991). Briefly, the cell-adhering active substance covers a plastic dish and a population of cells to be assayed is put into medium, allowing to stand for 30 minutes to 2 hours. After this incubation period, non-adhered cells are recovered, counted and assayed for viability. Cells adhered to the cell-adhering active substance are recovered using trypsin or a cell dissociation buffer (for example, Gibco), counted and tested for viability. Then, a proportion of adhered cells is calculated and compared with standard or standard control such as a plastic dish covered with bovine serum albumin (BSA). A combination of cell-adhering active substance/cell can be determined by substantial adhesion of the target cell with the cell-adhering active substance assayed. In addition, the cell-spreading activity can be determined by observing under a microscope a change in the form before adhered cells are dissociated using trypsin or a cell dissociation buffer, in the above procedures. Examples of the cell-adhering active substance include, for example, a cell-adhering active polypeptide or a functional equivalent thereof and a cell-adhesive synthetic polymer. Examples of the polypeptide, used in the present invention, having the cell-adhering activity include a cell-adhering active polypeptide such as invasin, polylysine and the like other than that derived from extracellular matrix, for example, a polypeptide showing the cell-spreading activity described in JP-A 2-311498, for example, components of an extracellular matrix such as fibronectin, laminin, collagen, vitronectin, osteopontin, thrombospondin, tenasin and the like. The extracellular matrix components can be prepared from a natural or cultured source by the known method [International Journal of Cancer, volume 20, page 1-5 (1977); Journal of Biological Chemistry, volume 254, page 9933-9937, (1979); "Zoku-Seikagaku Jikkenkoza, volume 6, Saibokokkaku no Kozo to Kino (Structure and Function of Cell Skeleton) (last volume), (1st edition) (1986) edited by Nippon Seikagakugakkai, published by Tokyo Kagakudojin; Cell Structure and Function, volume 13, page 281-292 (1988); Journal of Biological Chemistry, volume 264, page 18202-18208 (1989); and Journal of Biological Chemistry, volume 260, page 12240-12245 (1985)]. The cell-adhering active polypeptide may be substantially purified extracellular matrices exhibiting the cell-adhering activity, substantially purified extracellular matrix fragments or a mixture thereof. More particularly, proteins and polypeptides having the cell-adhering activity or the cell-spreading activity, or a functional equivalent thereof may be used. As these cell-adhering active polypeptides, substantially purified natural polypeptides, polypeptides from enzymological or chemical degradation of the natural polypeptides, or the similar polypeptides made by genetic engineering may be used. Further, materials obtained by altering these polypeptides without impairing the function, that is, the cell-adhering activity or the cell-spreading activity may be used. In the present invention, even when the amino acid sequence of a polypeptide from natural origin has deletion, substitution, addition and/or insertion of an amino acid, as long as the polypeptide has the desired cell-adhering activity or the cell-spreading activity, it is referred to as a functional equivalent of a polypeptide having the natural amino acid sequence. That is, it is known that naturally occurring proteins include proteins of which amino acid sequences have mutation such as deletion, insertion, addition, substitution and the like of an amino acid due to modification reaction in the living body after production or during purification, in addition to proteins having a change in the amino acid sequence due to polymorphism or mutation of genes encoding those naturally occurring proteins and that, regardless of these, there are proteins exhibiting the physiological and biological activity substantially equivalent to that of proteins having no mutation. Like this, even when there is a structural difference between polypeptides, as long as they share the common main functions, they are called polypeptides having the functionally equivalent activity. This is also true where the above mutations are artificially introduced into the amino acid sequence of proteins. In this case, more variety of mutants may be made. As long as these mutants exhibit the physiological activity substantially equivalent to that of proteins having no mutation, they are interpreted to be a polypeptide having the functionally equivalent activity. For example, in many cases, a methionine residue present at a N-terminal of a protein expressed in Escherichia coli is said to be removed by an action of methionine aminopeptidase, thus, generating both proteins having a methionine residue or those having no methionine residue depending upon the kind of proteins. However, whether or not a protein has a methionine residue dose not affect on the protein activity in many cases. In addition, it is known that a polypeptide where a certain cysteine residue is substituted with a serine residue in the amino acid sequence of human interleukin-2 (IL-2) retains the interleukin-2 activity [Science, volume 224, page 1431 (1984)]. Further, upon production of proteins by genetic engineering, it is frequently conducted that the proteins are expressed as a fused protein. For example, in order to increase an amount of an expressed protein of interest, it is conducted that the protein is expressed by adding a N-terminal peptide chain derived from other protein to a N-terminal of the protein of interest, or adding a suitable peptide chain to a N-terminal or a C-terminal of the protein of interest to facilitate purification of the protein of interest by using a carrier having the affinity to the added peptide chain. In this respect, the related biotechnological techniques have progressed and, as the result, deletion, substitution, addition or other modification of an amino acid in a functional area of a subject can be routinely carried out. Then, the resulting amino acid sequence may be routinely screened for the desired cell-adhering activity or the cell-spreading activity according to the above method. Polypeptides having the cell-adhering activity may be an artificial polypeptide containing, in the molecule, the amino acid sequence necessary for the cell-adhering activity, for example, the amino acid sequence may be selected from the amino acid sequence represented by SEQ ID: No. 1 (RGDS), the amino acid sequence represented by SEQ ID: No. 2 (CS1) and the amino acid sequence represented by SEQ ID: No. 6 (central sequence of laminin, YIGSR). These polypeptides can be prepared in a large amount by a genetic engineering method or chemical synthesis method and may be used as a purified polypeptide. Examples of the artificial polypeptide having, in the molecule, the amino acid sequence represented by SEQ ID: No. 1 include a polypeptide represented by SEQ ID: NO. 7 described in JP-A 1-180900. The polypeptide can be prepared using Escherichia coli HB101/pTF1409 (FERM BP-1939) according to a method described in JP-A 1-180900. In addition polypeptides represented by respective sequence ID numbers in the sequence list shown in Table 1 below can be prepared according to a genetic engineering method described in each specification. In addition, a plasmid pCHV90 contained in Escherichia coli HB101/pCHV90 in Table 1 can be prepared using Escherichia coli HB101/pHD101 (FERM BP-2264) and Escherichia coli JM109/pTF7021 (FERM BP-1941) according to a method described in JP-A 5-271291. Laid Open publication SEQ ID: No. Living bacterium (Escherichia coli) Accession No. JP-A 1-206998 8 JM109/pTF7021 FERM BP-1941 JP-A 1-261398 9 HB101/pTF1801 FERM P-9948 JP-A 2-97397 3 JM109/pTF7221 FERM BP-1915 JP-A 2-152990 10 JM109/pTFB800 FERM BP-2126 JP-A 2-311498 11 HB101/pCH101 FERM BP-2799 JP-A 3-59000 12 JM109/pCF406 FERM P-10837 JP-A 3-232898 13 HB101/pCE102 FERM P-11226 JP-A 4-54199 14 JM109/pTF7520 +VN-IN.TAA FERM P-11526 15 JM109/pTF7520 +Col X1 FERM P-11527 JP-A 5-271291 16 HB101/pCHV179 FERM P-12183 17 HB101/pCHV90 - 18 HB101/pCHV89 FERM P-182 JP-A 5-97698 19 JM109/pTF7520ColV FERM BP-5277 JP-A 5-178897 20 JM109/pYMH-CF•A FERM BP-5278 Alternatively, artificial polypeptides having, in the molecule, the amino acid sequence represented by SEQ ID: No. 1 can be chemically synthesized. For example, PolyRGDS described in JP-A 3-173828 can be synthesized and used. Examples of artificial polypeptides having, in the molecule, the amino acid sequence represented by SEQ ID: No. 2 include a polypeptide represented by SEQ ID: No. 4 described in JP-A 2-311498 and the polypeptide can be prepared by genetic engineering using Escherichia coli HB101/pHD102 (FERM P-10721) according to a method described in JP-A 2-311498. In addition, a polypeptide represented by SEQ ID: No. 2 may be chemically synthesized according to a method described in JP-A 3-284700. Further, examples of artificial polypeptides having, in the molecule, the amino acid sequence represented by SEQ ID: No. 2 and the amino acid sequence represented by SEQ ID: No. 3 include a polypeptide represented by SEQ ID: No. 21 described in JP-A 2-311498 and the polypeptide can be prepared by genetic engineering using Escherichia coli HB101/pCH102 (FERM BP-2800) according to a method described in JP-A 2-311498. In addition, a polypeptide represented by SEQ ID: No. 5 described in JP-A 3-284700 is a polypeptide containing, in the molecule, the amino acid sequences of SEQ ID: No. 1 and 2 and the polypeptide can be prepared by genetic engineering using Escherichia coli HB101/pCS25 (FERM P-11339) according to a method described in JP-A 3-284700. As described above, examples of the polypeptides used in the present invention are cell-adhering active polypeptides containing, in the molecule, the amino acid sequence represented by SEQ ID: No. 1 and/or the amino acid sequence represented by SEQ ID: No. 2. As the polypeptide, a polypeptide obtained by covalently binding a polypeptide derived from a cell adhesion domain of human fibronectin ["Fibronectin", page 47-121 (1989), edited by Mosher, D.F., published by Academic Press] with a CS1 polypeptide derived from the same (ibid), a polypeptide derived from a heparin binding domain (ibid) containing a CS1 polypeptide, or a polypeptide derived from a cell adhesion molecule can be used, and they can be made by genetic engineering, respectively. For example, respective necessary regions are taken out from a vector containing a DNA encoding a cell adhesion domain-derived polypeptide, a vector containing a DNA encoding a CS1 polypeptide, and a vector containing a DNA encoding a heparin binding domain-derived peptide containing a CS1 polypeptide, respectively, and they can be used alone or in combination thereof to make a vector expressing a polypeptide containing, in the molecule, the amino acid sequence represented by SEQ ID: No. 1 and/or the amino acid sequence represented by SEQ ID: No. 2. When a polypeptide where a polypeptide containing, in the molecule, the amino acid sequence represented by SEQ ID: No. 1 and a polypeptide containing, in the molecule, the amino acid sequence represented by SEQ ID: No. 2 are covalently bound is made, a covalent bonding between polypeptides may be a direct bonding or an indirect bonding, for example, an indirect bonding via a spacer. A spacer is an insertion sequence for adjusting an intermolecular distance in each region. As the spacer, an arbitral peptide chain can be used, for example, a sequence upstream of a CS1 region in fibronectin molecule. The spacer sequence can be easily introduced therein by genetic engineering. The cell-adhesive synthetic polymers include the known poly-N-p-vinylbenzyl-D-lactoneamide (PVLA). In the present invention, the target cell include, but being not limited to, hematopoiesis stem cell, peripheral blood stem cell, umbilical blood cell, ES cell, lymphocyte, cancer cell and the like. Examples of the foreign gene include, but being not limited to, nucleic acid selected from nucleic acids encoding proteins, nucleic acids encoding polypeptides, antisense DNA's, antisense RNA's, ribozymes, nucleic acids encoding intracellular antibodies and pseudogenes (decoy genes). In the present invention, the foreign gene may be inserted into a vector. Examples of the vector are retrovirus vector, adenovirus vector, vacciniavirus vector, herpesvirus vector and the like. According to the present invention, a target cell into which a foreign gene has been transferred by a perforation method according to a conventional method can be cultured in the presence of a cell-adhering active substance to effectively obtain transfected cells with a transferred gene. A cell culture method may be selected from the known methods depending upon a cell used. For example, when cell culturing is performed in the presence of a cell-adhering active polypeptide, 250 to 2000 µg/ml of the cell-adhering active polypeptide may be used in a culture medium to culture it according to a conventional method. Particularly, culturing is preferably carried out using a culture wear covered with a cell-adhering active substance. The culture wear refers to any wear normally used for cell culture, for example, a culture dish, a culture wear using a microcarrier, and a culture wear using fibrous hollow fibers. The culture wear may be covered with the substance by coating or spraying. For example, the culture wear may be easily covered with the cell-adhering active substance. The culture wear may be easily covered with the polypeptide by dissolving it in a suitable solution such as a phosphate buffered saline (PBS), adding the solution to the culture wear and allowing to stand for a suitable period of time. An amount of the polypeptide with which the culture wear is covered may be selected from a range of 50 to 1000 pmol/cm 2 , suitably 150 to 600 pmol/cm 2 . Transfected cells which have been cultured in the presence of the cell-adhering active substance can be obtained from a culture according to a conventional method. Thus, transfected cells can be produced effectively. The resulting transfected cells are useful for production of useful substances by cells using gene recombination techniques, exploitation of disease models, gene therapy and the like. Thus, transfected cells can be effectively produced according to the present invention. In addition, the present invention can be simply carried out by using a kit containing a cell-adhering active substance. The cell-adhering active substance to be contained in the kit may be in a form of solutions or lyophilized powders. The kit may contain a buffer for dissolving or diluting the cell-adhering active substance, a cell culture medium, a cell culture wear and the like. For example, a transfected cell can be simply produced by preparing a kit combining polypeptides, PBS for diluting the polypeptide, a cell culture wear and the like which are used for the method of the present invention. A reagent contained in the kit may be liquid or lyophilized. A perforation method in the present invention can be used by appropriately selecting from an electroporation method, a microinjection method, a particle gun method and the like depending upon the purpose. The present invention is illustrated by Examples below but is not limited to them. Example 1 1. Coating of cell-adhering active polypeptide on culture dish A polypeptide represented by SEQ ID: No. 3 (hereinafter referred to as "C274"), a polypeptide represented by SEQ ID: No. 4 (hereinafter referred to as "H296") and a polypeptide represented by SEQ ID: No. 5 (hereinafter referred to as "C•CS1") were dissolved in a phosphate buffered saline (PBS) to each 1 µM, respectively, which were steriled using a 0.22 µm filter (Millex-GV, Millipore). Each 1 ml/well of these solutions was added to a 24-well polystyrene culture dish (manufactured by Corning), respectively, to coat the dish at 4 °C overnight. These dishes were rinsed with a 500 µl/well of a Dulbecco's modified minimum basal medium containing no bovine fetal serum prior to addition of a transformed cell described below. 2. Transfection of cells Two culture dishes (diameter: 100 mm) of human epidermoid cancer cell A-431 which had been cultured in a Dulbecco's modified minimum basal medium containing 10% bovine fetal serum were rinsed with 10 ml of a Dulbecco's modified minimum basal medium containing no bovine fatal serum, respectively, and 3 ml of PBS containing 0.25% bovine trypsin and 0.02% EDTA was added thereto to detach cells from the culture dish. To these was added 7 ml of a Dulbecco's modified minimum basal medium containing no bovine fetal serum, followed by centrifugation at 800 rpm for 3 minutes to collect cells. The resulting cells were suspended in 10 ml of a Dulbecco's modified minimum basal medium containing bovine fetal serum, followed by centrifugation at 800 rpm for 3 minutes to collect cells. The resulting cells were combined, suspended in 10 ml of PBS, a 3/10 aliquot of the suspension was taken and divided into two equal aliquots, which were centrifuged at 800 rpm for 3 minutes to collect cells, respectively. The resulting cells were suspended again in 10 ml of PBS, followed by centrifugation at 800 rpm for 3 minutes to collect two batches of cells. One batch of the resulting cells were suspended in 1 ml of PBS containing 15 µg of pCAT-control vector (Promega) which had been aseptically prepared, and placed in an electroporation cuvette for Gene Pulser (BioRad), which were allowed to stand in ice for 10 minutes. The other batch of the resulting cells were suspended in 1 ml of PBS, and placed in an electroporation cuvette for Gene Pulser (BioRad), which were allowed to stand in ice for 10 minutes. Each batch of cells were allowed to stand in ice for 10 minutes, and voltage was applied thereto at 250V and 960 µF. After application, the cells were allowed to stand in a cuvette in ice for 10 minutes. Thereafter, the cells were recovered into 15 ml of a Dulbecco's modified minimum basal medium containing 10% bovine fetal serum, 1 ml/well of which were added to a 24-well polystyrene culture dish covered with the above polypeptide. These cells were cultured at 37 °C in the presence of 5% CO 2 gas overnight, the medium was removed by aspiration, and 1 ml/well of a fresh Dulbecco's modified minimum basal medium containing 10% bovine fetal serum was added thereto, followed by culturing at 37 °C in the presence of 5% CO 2 gas overnight. 3. Determination of transfection efficacy (efficacy of gene transfer) The cultured cells were rinsed three times with 1.25 ml of PBS per well, a lysed cell solution was prepared, and detection of expressed CAT was carried out using CAT-ELISA kit (manufactured by Boehringer Mannheim) according to a method for using the present kit. Since the present kit used a horseradish peroxidase-labelled secondary antibody and ABTS as a substrate, a ratio of 405nm/490nm was determined. An value obtained by subtracting a blank value from a value for each group in a case of addition of pCAT-control vector using as a blank a group in a case of no addition of pCAT-control vector upon electroporation was adopted as an amount of expressed CAT. The results thereof are shown in Fig. 1. That is, Fig. 1 is a view showing efficacy of gene transfer into a cell in each polypeptide-treatment group, where the ordinate shows non-treated group and each polypeptide-treatment group and the abscissa shows gene transfer efficacy expressed as a ratio of absorbance at 405 nm relative to that at 490 nm. As shown in Fig. 1, an amount of expressed CAT in the culture dish in the C274, H296 or C•CS1-treatment group is higher as compared with that in a non-treatment group, demonstrating that efficacy of transfer of pCAT-control vector into a cell is higher. Example 2 1. Coating of cell-adhering active polypeptide on culture dish A polypeptide represented by SEQ ID: No. 3 (hereinafter referred to as "C274"), a polypeptide represented by SEQ ID: No. 4 (hereinafter referred to as "H296") and a polypeptide represented by SEQ ID: No. 5 (hereinafter referred to as "C•CS1") were dissolved in a phosphate buffered saline (PBS) to each 1 µM, respectively, which were steriled using a 0.22 µm filter (Millex-GV, Millipore). 1 ml/well of these solutions were added to a 24-well polystyrene culture dish (manufactured by Corning) to coat the dish at 4 °C overnight, respectively. These dishes were rinsed with 500 µl/well of a Dulbecco's modified minimum basal medium containing no bovine fetal serum prior to addition of a transformed cell described below. 2. Transfection of cell Two culture dishes (diameter: 100 mm) of African green monkey kidney cell COS-7 which had been cultured in a Dulbecco's modified minimum basal medium containing 10% bovine fetal serum were rinsed with 10 ml of a Dulbecco's modified minimum basal medium containing no bovine fatal serum, respectively, and 3 ml of PBS containing 0.25% bovine trypsin and 0.02% EDTA was added thereto to detach cells from the culture dish. To these was added 7 ml of a Dulbecco's modified minimum basal medium containing no bovine fetal serum, respectively, followed by centrifugation at 800 rpm for 3 minutes to collect cells. The resulting cells were suspended in 10 ml of a Dulbecco's modified minimum basal medium containing bovine fetal serum, followed by centrifugation at 800 rpm for 3 minutes to collect cells. The resulting cells were combined, suspended in 12 ml of PBS, a 5/6 aliquot of the suspension was taken and divided into two equal aliquots, which were centrifuged at 800 rpm for 3 minutes to collect cells, respectively. The resulting cells were suspended in 6 ml of PBS, followed by centrifugation at 800 rpm for 3 minutes to collect two batches of cells. One batch of the resulting cells were suspended in 1 ml of PBS containing 15 µg of pCAT-control vector (Promega) which had been aseptically prepared, and placed in an electroporation cuvette for Gene Pulser (BioRad), which was allowed to stand in ice for 10 minutes. The other batch of the resulting cells were suspended in 1 ml of PBS, and placed in an electroporation cuvette for Gene Pulser (BioRad), which was allowed to stand in ice for 10 minutes. Each batch of cells were allowed to stand in ice for 10 minutes, and voltage was applied thereto at 250V and 960 µF. After application, the cells were allowed to stand in a cuvette in ice for 10 minutes. Thereafter, the cells were recovered into 15 ml of a Dulbecco's modified minimum basal medium containing 10% bovine fetal serum, 1 ml/well of the cells were added to a 24-well polystyrene culture dish covered with the above polypeptide. These cells were cultured at 37 °C in the presence of 5% CO 2 gas overnight, the medium was removed by aspiration, and 1 ml/well of a fresh Dulbecco's modified minimum basal medium containing 10% bovine fetal serum was added, followed by culturing at 37 °C in the presence of 5% CO 2 gas overnight. 3. Determination of transfection efficacy (efficacy of gene transfer) The cultured cells were rinsed three times with 1.25 ml of PBS per well, a lysed cell solution was prepared, and detection of expressed CAT was carried out using CAT-ELISA kit (manufactured by Boehringer Mannheim) according to a method for using the present kit. Since the present kit used a horseradish peroxidase-labelled secondary antibody and ABTS as a substrate, a ratio of 405nm/490nm was determined. An value obtained by subtracting a blank value from a value for each group in a case of addition of pCAT-control vector using as a blank a group in a case of no addition of pCAT-control vector upon electroporation was adopted as an amount of expressed CAT. The results thereof are shown in Fig. 2. That is, Fig. 2 is a view showing efficacy of gene transfer into a cell in each polypeptide-treatment group, where the ordinate shows non-treated group and each polypeptide-treatment group and the abscissa shows gene transfer efficacy expressed as a ratio of absorbance at 405 nm relative to that at 490 nm. As shown in Fig. 2, an amount of expressed CAT in the culture dish in the above C274, H296 or C•CS1-treatment group is higher as compared with that in a non-treatment group, demonstrating that efficacy of transfer of pCAT-control vector into a cell is higher. Example 3 Preparation of kit A kit for production of gene-transfered cells was made from C274, H296, C•CS1, PBS and a culturing dish as shown in Table 2 below. Reagents A, B and C were prepared so that the above polypeptides were adjusted with PBS to indicated concentrations shown in the Table. Other components were used which are described in Example 1. In addition, all of reagents A, B and C and a diluent for reagents were aseptically prepared by pre-filtering with a 0.22 µm sterile filter. Kit for production of transfected cell Reagent A•••100 µM C274 150 µl Reagent B•••100 µM H296 150 µl Reagent C•••100 µM C•CS1 150 µl Diluent for reagents•••PBS 45 ml 24-well polystyrene culture dish 3 As described above, the present invention can overcome the problems of the previous methods for gene transfer into cells and provide a method, for production of transfected cells, having improved efficacy of gene transfer into target cells. The present invention can also provide a kit, for production of transfected cells, which are used for the method. BRIEF DESCRIPTION OF DRAWINGS Fig. 1 is a graph showing the effect of cell-adhering active polypeptide treatment on gene transfer efficacy in transfer of pCAT-control vector into human epidermoid cancer cell A-431. Fig. 2 is a graph showing the effect of cell-adhering active polypeptide treatment on gene transfer efficacy in transfer of pCAT-control vector into African green monkey kidney cell COS-7. Sequence Listing (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Takara Shuzo Co., Ltd. (B) STREET: 609, Takenaka-cho, Fushimi-ku (C) CITY: Kyoto-shi, Kyoto (E) COUNTRY: Japan (F) ZIP: 612 (ii) TITLE OF INVENTION: Method for production of transfected cells (iii) NUMBER OF SEQUENCES: 21 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb (B) COMPUTER: IBM PS/2 Model 50Z or 55SX (C) OPERATING SYSTEM: MS-DOS (Version 5.0) (D) SOFTWARE: Microsoft Word (v) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: EP 95 93 8599.8 (B) FILING DATE: (vi) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: PCT/JP95/02425 (B) FILING DATE: 29. November 1995 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 274 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 296 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 302 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 283 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 279 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 474 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 385 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 549 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 422 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 332 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 341 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 446 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 457 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 368 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 367 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 464 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 432 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 574 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

Claims: In a method for production of transfected cells by transferring a foreign gene into target cells using a perforation method, said method for production of cells transfected with a foreign gene which comprises a step of, after injection of a foreign gene into target cells using a perforation method, culturing the cells in the presence of a cell-adhering active polypeptide containing the amino acid sequence represented by SEQ ID NO:1 and/or the amino acid sequence represented by SEQ ID NO:2. The method for production of transfected cells according to claim 1, the culturing step is a step of culturing using a culture wear covered with a cell-adhering active polypeptide containing the amino acid sequence represented by SEQ ID NO:1 and/or the amino acid sequence represented by SEQ ID NO:2. The method for production of transfected cells according to claim 1, wherein the cell-adhering active polypeptide is a cell-adhering and/or cell-spreading active polypeptide. The method for production of transfected cells according to claim 1, wherein the cell-adhering active polypeptide is selected from polypeptides represented by SEQ ID Nos:3, 4 and 5. The method for production of transfected cells according to claim 1, wherein the target cells are selected from hematopoiesis stem cell, peripheral blood stem cell, umbilical blood cell, ES cell, lymphocyte and cancer cell. The method for production of transfected cells according to claim 1, wherein the foreign gene is nucleic acid selected from nucleic acids encoding proteins, nucleic acids encoding polypeptides, antisense DNAs, antisense RNAs, ribozymes, nucleic acids encoding intracellular antibodies and pseudogenes (decoy genes). The method for production of transfected cells according to claim 1, wherein the foreign gene is nucleic acid selected from nucleic acids encoding proteins, nucleic acids encoding polypeptides, antisense DNAs, antisense RNAs, ribozymes, nucleic acids encoding intracellular antibodies and pseudogenes (decoy genes) and the nucleic acid is incorporated into the vector. The method for production of transfected cells according to claim 1, wherein the vector is a vector selected from retrovirus vector, adenovirus vector, vacciniavirus vector and herpesvirus vector. The method for production of transfected cells according to claim 1, the perforation method is selected from an electroporation method, a microinjection method and a particle, gun method. Transfected cells produced by a method for production of transfected cells according to claim 1. A kit for production of transfected cells with a foreign gene which is used in a method for production of transfected cells according to claim 1, said kit comprising a cell-adhering active polypeptide containing the amino acid sequence represented by SEQ ID NO:1 and/or the amino acid sequence represented by SEQ ID NO:2.

Inventors: HASHINO KIMIKAZU, KATO IKUNOSHIN, MATSUSHITA HIDEYUKI, HASHINO, KIMIKAZU, KATO, IKUNOSHIN, MATSUSHITA, HIDEYUKI, MATSUSHITA, Hideyuki, Hamoparesu-Kusatsu 401
Applicants: TAKARA SHUZO CO, TAKARA SHUZO CO. LTD.
Application year: 1995
Main classification: C12N15
IPC codes: C12N15, C07K14, C12N5